Raymond James Financial’s SpringWorks Therapeutics SWTX Stock Holding History

Raymond James Financial’s Portfolio SWTX Stock Details SWTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-159	Closed	-$7.47K	–	6574
2025 Q2	$7.47K	Sell	159 -141,194	-100%	-$6.28M	﹤0.01%	6041
2025 Q1	$6.24M	Sell	141,353 -150,003	-51%	-$6.9M	﹤0.01%	2179
2024 Q4	$10.5M	Buy	+291,356	New	+$10.2M	﹤0.01%	1807

Other funds holding SWTX

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Raymond James Financial's SWTX Position: Q3 2025 in Review

Raymond James Financial sold out of SpringWorks Therapeutics (SWTX) in Q3 2025, closing a stake of 159 shares — an estimated $7.47K sold.

Raymond James Financial first reported a position in SWTX in Q4 2024 and held it in 3 quarters. The position peaked at $10.5M in Q4 2024. 3 funds tracked by Wall St. Rank hold SWTX as of Q3 2025.

Raymond James Financial reported no remaining SpringWorks Therapeutics position as of Q3 2025 after selling out during the quarter.
Raymond James Financial sold 159 SpringWorks Therapeutics shares in Q3 2025, an estimated $7.47K.
Raymond James Financial first reported a position in SpringWorks Therapeutics in Q4 2024 and held it in 3 quarters.
Raymond James Financial's SpringWorks Therapeutics position peaked at $10.5M in Q4 2024.
3 funds tracked by Wall St. Rank held SpringWorks Therapeutics as of Q3 2025.

Based on Raymond James Financial's 13F filing for Q3 2025, filed 14 Nov 2025.